Design of Development Candidate eFT226, a First in Class Inhibitor of Eukaryotic Initiation Factor 4A RNA Helicase
- 29 May 2020
- journal article
- research article
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 63 (11), 5879-5955
- https://doi.org/10.1021/acs.jmedchem.0c00182
Abstract
Dysregulation of protein translation is a key driver for the pathogenesis of many cancers. Eukaryotic initiation factor 4A (eIF4A), an ATP-dependent DEAD-box RNA helicase, is a critical component of the eIF4F complex, which regulates cap-dependent protein synthesis. The flavagline class of natural products (i.e., rocaglamide A) has been shown to inhibit protein synthesis by stabilizing a translation–incompetent complex for select messenger RNAs (mRNAs) with eIF4A. Despite showing promising anticancer phenotypes, the development of flavagline derivatives as therapeutic agents has been hampered because of poor drug-like properties as well as synthetic complexity. A focused effort was undertaken utilizing a ligand-based design strategy to identify a chemotype with optimized physicochemical properties. Also, detailed mechanistic studies were undertaken to further elucidate mRNA sequence selectivity, key regulated target genes, and the associated antitumor phenotype. This work led to the design of eFT226 (Zotatifin), a compound with excellent physicochemical properties and significant antitumor activity that supports clinical development.Keywords
This publication has 40 references indexed in Scilit:
- Structure-based Design of Pyridone–Aminal eFT508 Targeting Dysregulated Translation by Selective Mitogen-activated Protein Kinase Interacting Kinases 1 and 2 (MNK1/2) InhibitionJournal of Medicinal Chemistry, 2018
- Mitogen-activated Protein Kinase (MAPK) Interacting Kinases 1 and 2 (MNK1 and MNK2) as Targets for Cancer Therapy: Recent Progress in the Development of MNK Inhibitors.Current Medicinal Chemistry, 2017
- Translation from unconventional 5′ start sites drives tumour initiationNature, 2017
- New frontiers in translational control of the cancer genomeNature Reviews Cancer, 2016
- eFT508, a Potent and Selective Mitogen-Activated Protein Kinase Interacting Kinase (MNK) 1 and 2 Inhibitor, Is Efficacious in Preclinical Models of Diffuse Large B-Cell Lymphoma (DLBCL)Blood, 2015
- eIF4F: A RetrospectiveOnline Journal of Public Health Informatics, 2015
- Targeting the translation machinery in cancerNature Reviews Drug Discovery, 2015
- Targeting the eIF4F Translation Initiation Complex: A Critical Nexus for Cancer DevelopmentCancer Research, 2015
- Cap‐Dependent Translation Initiation Factor eIF4E: An Emerging Anticancer Drug TargetMedicinal Research Reviews, 2012
- The biological and therapeutic relevance of mRNA translation in cancerNature Reviews Clinical Oncology, 2011